Active substanceOrotic acidOrotic acid
Similar drugsTo uncover
  • Potassium orotate
    pills inwards 
  • Potassium orotate
    pills inwards 
    AVVA RUS, OJSC     Russia
  • Potassium orotate
    pills inwards 
    AVEKSIMA, JSC     Russia
  • Potassium orotate
    pills inwards 
    UPDATE OF PFC, CJSC     Russia
  • Potassium orotate
    pills inwards 
  • IRBITSK HFZ, OJSC     Russia
  • Dosage form: & nbsppills
    Composition:

    Active substance: potassium orotate -500.0 mg.

    Excipients: lactose monohydrate - 166.0 mg, potato starch - 70.0 mg. magnesium stearate -2.0 mg, stearic acid 5.0 mg, gelatin 7.0 mg.

    Description:Tablets are white, flat-cylindrical, with a facet and a risk.
    Pharmacotherapeutic group:Metabolic means
    ATX: & nbsp

    A.12.C.X   Preparations of other minerals

    Pharmacodynamics:

    Orotic acid is one of the precursors of pyrimidine nucleotides that are part of the nucleic acids that are involved in the synthesis of protein molecules, and therefore, the salts of orotic acid are considered as anabolic agents and are used in the disturbances of protein metabolism to stimulate them. Usually potassium salt of orotic acid (potassium orotate) is used.Potassium orotate stimulates the synthesis of nucleic acids, the production of albumin in the liver (especially in conditions of prolonged hypoxia), increases appetite, has a diuretic, regenerating properties.

    Pharmacokinetics:

    After oral administration in the gastrointestinal tract, 10% of the dose taken internally is absorbed. It is converted in the liver into orotidin-5-phosphate. It is excreted by the kidneys (30% in the form of various metabolites).

    Indications:

    - As an auxiliary for liver diseases (caused by acute and chronic intoxication, with the exception of organic lesions of the liver (true cirrhosis with ascites);

    - as part of a combination therapy for chronic heart failure and heart rhythm disturbances;

    - alimentary and alimentary-infectious hypotrophy in children;

    - chronic physical overstrain.

    Contraindications:

    - Hypersensitivity to any of the components of the drug;

    - acute and chronic organic liver damage (including cirrhosis of the liver with ascites);

    - nefroourolithiasis;

    - kidney failure;

    - children under 3 years (solid dosage form).

    Due to the presence of lactose, patients with rare hereditary diseases,such as: lactose intolerance, lactase deficiency or glucose-galactose malabsorption, should not take the drug.

    Carefully:

    Pregnancy and lactation.

    Pregnancy and lactation:Carefully.
    Dosing and Administration:

    Take inside 1 hour before meals or 4 hours after meals.

    Adults on 250-500 mg 2-3 times a day. The course of treatment lasts an average of 20-30 days. If necessary, treatment can be repeated after 1 month. In exceptional cases, you can increase the dose of adults to 3 grams per day.

    Children - 10-20 mg / kg body weight per day. The course of treatment is 3-5 weeks.

    Side effects:

    Usually, potassium orotate is well tolerated. In some cases, allergic skin reactions may occur, which disappear after the interruption of treatment. Potassium orotate can also cause digestive disorders (nausea, vomiting, diarrhea). When used in high doses against the background of a low protein diet, it is possible to develop liver dystrophy. If side effects occur, consult a physician.

    Overdose:

    Data on overdose are absent.

    Interaction:Astringent and enveloping agents can somewhat reduce the absorption of potassium orotate in the gastrointestinal tract.It is difficult to assimilate iron, tetracycline, sodium fluoride (the interval between taking the drug is at least 2-3 hours). Oral contraceptives, diuretics, muscle relaxants, glucocorticoid agents, insulin reduce the effect of the drug.
    Special instructions:

    Does not cause drowsiness and decrease the speed of psychomotor reactions.

    Form release / dosage:

    Tablets 500 mg.

    Packaging:

    10 tablets per contour cell pack.

    For 10 tablets in a contour non-cellular package.

    For 60 tablets in a jar of polymer materials.

    1 jar or 2, 3, 4, 5, 6 contour mesh packages with instructions for medical use are placed in a pack of cardboard.

    500 contour non-jammed packages with an equal number of instructions on medical application is placed in a group package (for hospitals).

    Storage conditions:At a temperature of no higher than 25 ° C. Keep out of the reach of children.
    Shelf life:

    4 years.

    Do not use after the expiration date.

    Terms of leave from pharmacies:Without recipe
    Registration number:LSR-003635/10
    Date of registration:30.04.2010 / 26.03.2015
    Expiration Date:Unlimited
    The owner of the registration certificate:AVEKSIMA, JSC AVEKSIMA, JSC Russia
    Manufacturer: & nbsp
    Representation: & nbspAVEKSIMA, JSC AVEKSIMA, JSC Russia
    Information update date: & nbsp26.11.2017
    Illustrated instructions
      Instructions
      Up